Middle East & Africa Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type (Cell Therapy {Allogeneic, Autologous, and Viral Vectors}, and Gene Therapy {Non-viral Vectors, and Viral Vectors}), Services (Process Development, cGMP Manuf

The Middle East & Africa cell and gene therapy market was valued at US$ 129.17 million in 2023 and is projected to reach US$ 469.34 million by 2031; it is estimated to record a CAGR of 17.5% from 2023 to 2031.

Automation of Cell and Gene Therapy Manufacturing Services Boosts Middle East & Africa Cell and Gene Therapy Market

Incorporating automation in cell and gene therapy manufacturing can lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices designed to boost the automation of most sequential unit operations for a CAR-T process within a single system. With the rise in demand for cell and gene therapies, the production of cell and gene therapy products has shifted from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to commercialization has propelled the demand for automation in commercial manufacturing. Further, government agencies are adopting automation in the manufacturing of cell therapies to increase national production capabilities. Thus, automation of cell and gene therapy manufacturing services is expected to bring new trends in the Middle East & Africa cell and gene therapy market in the coming years.

Middle East & Africa Cell and Gene Therapy Market Overview

South Africa is a developing nation. The proper implementation of a cell therapy program in South Africa can result in the reduction of the high disease burden in the country; however, the cost of cell and gene therapy restricts South African patients' access to these therapies. Despite being technologically more advanced than other African nations, gene therapy manufacturing is still not widely available in South Africa. The most problematic aspects are the lack of funding, human resources, and awareness about therapy. Although the South African government has made efforts to support the biotechnology industry, cell therapy has not received enough attention. Moreover, the scientific and medical community is highly innovative and focused on cell and gene therapy.

Middle East & Africa Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Cell and Gene Therapy Market Segmentation

The Middle East & Africa cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Middle East & Africa cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Middle East & Africa cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Middle East & Africa cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Middle East & Africa cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Middle East & Africa cell and gene therapy market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Middle East & Africa cell and gene therapy market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa cell and gene therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa cell and gene therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa cell and gene therapy market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.